🇺🇸 FDA
Patent

US 11464768

Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

granted A61KA61K31/13A61K31/135

Quick answer

US patent 11464768 (Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis) held by ACADIA Pharmaceuticals Inc. expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/13, A61K31/135, A61K31/27, A61K31/343